Oseltamivir-resistant pandemic (H1N1) 2009 virus, South Korea

Emerging Infectious Diseases

Volumn 16, Issue 12, 2010, Pages 1938-1942

  Yi, Hwajung ^a   Lee, Joo Yeon ^a   Hong, Eun Hye ^a   Kim, Mi Seon ^a   Kwon, Donghyok ^a   Choi, Jang Hoon ^a   Choi, Woo Young ^a   Kim, Ki Soon ^a   Lee, Jong Koo ^a   Oh, Hee Bok ^a   Kang, Chun ^a  

^a Korea Centers for Disease Control and Prevention   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; OSELTAMIVIR; PERAMIVIR; RIBAVIRIN; ZANAMIVIR;

ADULT; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG SENSITIVITY; FEMALE; GENOTYPE; HUMAN; IC 50; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; MALE; MYELODYSPLASTIC SYNDROME; NUCLEOTIDE SEQUENCE; PANDEMIC INFLUENZA; SOUTH KOREA; VIRUS ISOLATION; VIRUS STRAIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CHILD, PRESCHOOL; DISEASE OUTBREAKS; DRUG RESISTANCE, VIRAL; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MOLECULAR SEQUENCE DATA; NEURAMINIDASE; OSELTAMIVIR; REPUBLIC OF KOREA; VIRAL PROTEINS;

EID: 78649561911     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1612.100600     Document Type: Article

References (8)

1. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360:2605-15. DOI: 10.1056/NEJMoa0903810
2. World Health Organization. Weekly update on oseltamivir resistance to pandemic influenza A (H1N1) 2009 update 99, April [cited 2010 Aug 31]. http://www.who.int/csr/disease/swineflu/oseltamivirresistant2010416.pdf
3. Yang IS, Lee JY, Lee JS, Mitchell WP, Oh HB, Kang C, et al. Influenza sequence and epitope database. Nucleic Acids Res. 2009;37:D423-30. DOI: 10.1093/nar/gkn881
4. Govorkova EA, Ilyushina NA, McClaren JL, Naipospos TS, Douangngeun B, Webster RG. Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. Antimicrob Agents Chemother. 2009;53:3088-96. DOI: 10.1128/AAC.01667-08
5. Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG. Susceptibility of highly pathogenic A (H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res. 2007;73:228-31. DOI: 10.1016/j.antiviral.2006.10.004
6. Update on oseltamivir resistant pandemic A (H1N1) 2009 influenza virus: January 2010. Wkly Epidemiol Rec. 2009;85:37-40.
7. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, Blackburn GM, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature. 2006;443:45-9. DOI: 10.1038/nature05114
8. Gubareva LV, Novikov DV, Hayden FG. Assessment of hemagglutinin sequence heterogeneity during influenza virus transmission in families. J Infect Dis. 2002;186:1575-81. DOI: 10.1086/345372